Contact
 

More than 450 research studies outlining the latest advances and obstacles in the search for an AIDS vaccine will be presented and debated at...

The NIH is offering R01 grants to help investigate structural and conformational features of HIV glycosylation that may lead to novel HIV vaccine design approaches; and to elucidate the impact of differential glycosylation on the quality of the...

Latebreaker Abstracts - July 29, 2013

The deadline to submit later breaker abstracts for AIDS Vaccine 2013 is 11 August.  To submit yours, visit http://precis.preciscentral.com/User...

The Enterprise and partners will focus on identifying synergies between therapeutic and preventive HIV vaccines and exploring strategies to generate long-lasting immune responses from an HIV vaccine

The Enterprise and partners held a consultation on 14 - 15 March 2013 around the issue of VISP/R.  The full meeting report is available to download below.

In a brief history of the global effort to develop a preventive HIV vaccine (Vaccine 2013, in press), Enterprise champion, Jose Esparza has set down the...

The Enterprise Secretariat attended the 2013 HVTN Full Group meeting in May and developed a report on sessions attended.  Check out the report here...

In a  Huffington Post opinion piece, Mitchell Warren, AVAC executive director, encourages the field to step up the pace further.

In a post, Margie McGlynn, IAVI CEO, reflects on progress and setback and calls for persevarance in pursuit of an AIDS vaccine,...

The Center for Strategic International Studies (CSIS) calls for perseverance in the research, development and testing of future vaccine candidates in response to last week's decision to stop the testing of a candidate HIV vaccine combination (...

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account